LUCRIN PDS DEPOT 11.25 MG

Χώρα: Ισραήλ

Γλώσσα: Αγγλικά

Πηγή: Ministry of Health

Δραστική ουσία:

LEUPRORELIN ACETATE

Διαθέσιμο από:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

Φαρμακολογική κατηγορία (ATC):

L02AE02

Φαρμακοτεχνική μορφή:

POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION

Σύνθεση:

LEUPRORELIN ACETATE 11.25 MG

Οδός χορήγησης:

I.M, S.C

Τρόπος διάθεσης:

Required

Κατασκευάζεται από:

ABBVIE LOGISTICS B.V., THE NETHERLANDS

Θεραπευτική περιοχή:

LEUPRORELIN

Θεραπευτικές ενδείξεις:

Endometriosis, prostatic cancer, treatment of uterine Fibroids for a period of up to six months. Treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

Ημερομηνία της άδειας:

2015-06-03

Φύλλο οδηγιών χρήσης

PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986
The medicine is dispensed with a doctor’s prescription only
LUCRIN
® PDS DEPOT 3.75 MG
LEUPRORELIN ACETATE 3.75 MG
Powder and solvent for suspension for injection
LUCRIN
® PDS DEPOT 11.25 MG
LEUPRORELIN ACETATE 11.25 MG
Powder and solvent for suspension for injection
Inactive ingredients and allergens in the medicine – see section 6
“Further
Information”.
Read this leaflet carefully in its entirety before using the medicine.
This leaflet
contains concise information about the medicine. If you have further
questions,
refer to the doctor or pharmacist.
This medicine has been prescribed to treat your ailment. Do not pass
it on to
others. It may harm them even if it seems to you that their ailment is
similar.
1. WHAT IS THE MEDICINE INTENDED FOR?
Lucrin PDS Depot is intended to treat:
• Endometriosis )migration of uterine mucosal tissue to outside of
the uterus)
for a period of up to six months
• Uterine fibroids )myomas) for a period of up to six months
• Prostate cancer for a period of up to six months
• Breast cancer in premenopausal and postmenopausal women who
require
hormonal treatment
Lucrin PDS Depot 11.25 mg is suitable for patients requiring hormonal
treatment
for a period of at least three months.
This medicine is not usually intended for infants and for children
under 18
years of age.
THERAPEUTIC GROUP: Inhibitor of gonadotropin secretion when given on a
continuous basis.
Leuprorelin is a synthetic nonapeptide analogue of the endogenous
hormone
Gonadotropin Releasing Hormone )GnRH; also known as LHRH). Its
mechanism
of action upon continuous administration is inhibition of secretion of
the
gonadotropins, resulting in suppression of secretion of sex hormones
from
the ovaries and testes.
Upon use of leuprorelin, LH, FSH and sex hormone levels drop.
2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE:
• if you are sensitive )allergic) to the active ingredient
)synthetic GnRH),
to similar nonape